Novartis (NVS) Projected to Post Earnings on Tuesday

Novartis (NYSE:NVS) will likely be announcing its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect the company to announce earnings of $2.13 per share and revenue of $13.5421 billion for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:00 AM ET.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.04. Novartis had a net margin of 25.65% and a return on equity of 40.53%. The company had revenue of $13.86 billion during the quarter, compared to analyst estimates of $13.85 billion. During the same period last year, the firm posted $1.98 EPS. Novartis’s revenue for the quarter was up 1.4% compared to the same quarter last year. On average, analysts expect Novartis to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Novartis Stock Performance

Shares of NYSE NVS opened at $145.36 on Friday. The stock has a market cap of $277.36 billion, a price-to-earnings ratio of 20.30, a PEG ratio of 2.53 and a beta of 0.52. Novartis has a 12 month low of $104.93 and a 12 month high of $170.46. The company has a 50 day simple moving average of $155.85 and a two-hundred day simple moving average of $143.48. The company has a current ratio of 1.12, a quick ratio of 0.89 and a debt-to-equity ratio of 0.60.

Novartis Announces Dividend

The firm also recently disclosed an annual dividend, which was paid on Monday, March 16th. Stockholders of record on Wednesday, March 11th were paid a $4.773 dividend. The ex-dividend date was Wednesday, March 11th. This represents a dividend yield of 306.0%. Novartis’s dividend payout ratio is presently 43.02%.

Institutional Investors Weigh In On Novartis

Hedge funds have recently modified their holdings of the company. Brighton Jones LLC boosted its stake in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after acquiring an additional 2,666 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Novartis by 48.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock worth $963,000 after acquiring an additional 2,581 shares in the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Novartis during the 2nd quarter worth about $202,000. Crawford Investment Counsel Inc. purchased a new stake in shares of Novartis during the 4th quarter worth about $202,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Novartis by 1,776.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,595 shares of the company’s stock valued at $193,000 after buying an additional 1,510 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on NVS shares. Citigroup reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, February 5th. Barclays raised shares of Novartis from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Weiss Ratings raised shares of Novartis from a “buy (b)” rating to a “buy (a-)” rating in a report on Friday, February 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, February 12th. Finally, Argus raised Novartis from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.